Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-232411 in Healthy Participants and Participants With Dry Eye
NCT02420730Phase 1Completed
- Sponsor
- Allergan
- Start
- Jun 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AGN-232411 in dry eye syndrome (DED) (8 cohorts), sponsored by Allergan. Primary endpoint: Percentage of Participants with Treatment Emergent Adverse Events at 56 days. Started Jun 2015; status: completed.
02
Drugs
AGN-232411
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02420730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420730.